Not Yet RecruitingNot Applicable

HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study

200 participantsStarted 2025-02-01

Plain-language summary

This multicenter, real-world study introduces a novel Hematoxylin-eosin staining(H\&E)-based four tumor microenvironment (TME) system (HEFTME system) assisting in prognostic prediction and precise adjuvant treatment selection for laUTUC postoperatively.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * pathological diagnose of UTUC; * Met more than muscle-invasion stages(pT2+) or lymph nodes metastasis. Exclusion Criteria: * Patients with early-local stages (pTa/T1/Tis) without LNM+ and those with incomplete pathologic and prognostic information were excluded

What they're measuring

DFS

Timeframe: 1 year, 3 years and 5 years

Trial details

NCT IDNCT06798246

SponsorPeking University First Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-01-01

Contact for this trial

Chunru Doc. Xu, M.D.

+86-17812172086 xcrbdyy@126.com

View on ClinicalTrials.gov More Upper Tract Urothelial Carcinoma trials